LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

Search

Cytek Biosciences Inc

Closed

SectorHealthcare

4.84 -3.01

Overview

Share price change

24h

Current

Min

4.83

Max

4.92

Key metrics

By Trading Economics

Income

105K

-5.5M

Sales

6.7M

52M

EPS

-0

Profit margin

-10.476

Employees

692

EBITDA

6.4M

-4.2M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+19.96% upside

Market Stats

By TradingEconomics

Market Cap

120M

621M

Previous open

7.85

Previous close

4.84

News Sentiment

By Acuity

17%

83%

19 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Cytek Biosciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 Dec 2025, 22:53 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 Dec 2025, 00:04 UTC

Acquisitions, Mergers, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 Dec 2025, 23:46 UTC

Market Talk

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 Dec 2025, 23:36 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 Dec 2025, 22:38 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 Dec 2025, 22:02 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 Dec 2025, 22:01 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 Dec 2025, 22:01 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 Dec 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 Dec 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 Dec 2025, 21:59 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Acquire Remaining 64% of Alta Copper

14 Dec 2025, 17:00 UTC

Earnings

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 Dec 2025, 08:30 UTC

Acquisitions, Mergers, Takeovers

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 Dec 2025, 16:48 UTC

Acquisitions, Mergers, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 Dec 2025, 08:00 UTC

Acquisitions, Mergers, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 Dec 2025, 07:00 UTC

Acquisitions, Mergers, Takeovers

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 Dec 2025, 00:24 UTC

Acquisitions, Mergers, Takeovers

Want a Piece Of SpaceX? -- Barrons.com

12 Dec 2025, 23:49 UTC

Acquisitions, Mergers, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 Dec 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 Dec 2025, 22:32 UTC

Earnings

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 Dec 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 Dec 2025, 20:45 UTC

Earnings

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 Dec 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 Dec 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 Dec 2025, 19:23 UTC

Earnings

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 Dec 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 Dec 2025, 18:33 UTC

Acquisitions, Mergers, Takeovers

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 Dec 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 Dec 2025, 17:49 UTC

Earnings

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 Dec 2025, 17:34 UTC

Acquisitions, Mergers, Takeovers

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Peer Comparison

Price change

Cytek Biosciences Inc Forecast

Price Target

By TipRanks

19.96% upside

12 Months Forecast

Average 5.83 USD  19.96%

High 7.5 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forCytek Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

3.7 / 3.8Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

19 / 374 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat